Literature DB >> 32053267

Selenium-Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy and Chemotherapy.

Shiqian Gao1,2, Tianyu Li1, Ye Guo3, Chenxing Sun1, Banruo Xianyu1, Huaping Xu1.   

Abstract

Considering the limited clinical benefits of individual approaches against malignancy, natural killer (NK) cell-mediated immunotherapy is increasingly utilized in combination with radiotherapy and target therapeutics. However, the interplay of targeted agents, immunotherapy, and radiotherapy is complex. An improved understanding of the effect of chemotherapy or radiotherapy on specific molecular pathways in immune cells would help to optimize the synergistic antitumor efficiency. In this study, the selenium-containing nanoparticles (NPs) could deliver the chemotherapeutic drug doxorubicin (DOX) to tumor sites by systemic administration. Radiation stimuli facilitate DOX release and enhance chemotherapy efficiency. Moreover, radiation could oxidize diselenide-containing NPs to seleninic acid, which have both synergistic antitumor effect and immunomodulatory activity through enhancing NK cells function. These results indicate that the selenium-containing NPs would be a potential approach to achieve simultaneous treatments of immunotherapy, chemotherapy, and radiotherapy by a simple but effective method.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer; immunotherapy; nanoparticles; radiotherapy; selenium

Year:  2020        PMID: 32053267     DOI: 10.1002/adma.201907568

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  25 in total

1.  The Relation Between Trace Elements and Latent Tuberculosis Infection: a Study Based on National Health and Nutritional Examination Survey 2011-2012.

Authors:  Rui Zhao; Wei Miao; Baohua Li
Journal:  Biol Trace Elem Res       Date:  2022-04-28       Impact factor: 3.738

2.  L-Selenocysteine induced HepG-2 cells apoptosis through reactive oxygen species-mediated signaling pathway.

Authors:  Kaiying Zhang; Jingyao Su; Danyang Chen; Binger Lin; Yucan Wu; Yibing Wang; Jiapei Lei; Ruilin Zheng; Bing Zhu; Yinghua Li
Journal:  Mol Biol Rep       Date:  2022-06-18       Impact factor: 2.742

3.  Construction of pH/reduction dual responsive MSN-HAgel containing HApt for tumor targeting carriers.

Authors:  Yehong Liu; Miaoxin Chen; Gaoyang Li; Shouhong Xu; Honglai Liu
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

Review 4.  Stimuli-responsive nanocarriers for therapeutic applications in cancer.

Authors:  Xubo Zhao; Jie Bai; Wenjing Yang
Journal:  Cancer Biol Med       Date:  2021-03-25       Impact factor: 4.248

Review 5.  Recent progress in nanomedicine for enhanced cancer chemotherapy.

Authors:  Guoqing Wei; Yu Wang; Guang Yang; Yi Wang; Rong Ju
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

Review 6.  Reactive Oxygen Species Responsive Polymers for Drug Delivery Systems.

Authors:  Fengxiang Gao; Zhengrong Xiong
Journal:  Front Chem       Date:  2021-04-23       Impact factor: 5.221

7.  Therapeutic Potential of Selenium and Selenium Compounds in Cervical Cancer.

Authors:  Ewa Jablonska; Qi Li; Edyta Reszka; Edyta Wieczorek; Kateryna Tarhonska; Tong Wang
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

Review 8.  Drug delivery carriers with therapeutic functions.

Authors:  Shuting S Cai; Tianyu Li; Tolulope Akinade; Yuefei Zhu; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2021-07-21       Impact factor: 17.873

9.  Small changes in the length of diselenide bond-containing linkages exert great influences on the antitumor activity of docetaxel homodimeric prodrug nanoassemblies.

Authors:  Lingxiao Li; Shiyi Zuo; Fudan Dong; Tian Liu; Yanlin Gao; Yinxian Yang; Xin Wang; Jin Sun; Bingjun Sun; Zhonggui He
Journal:  Asian J Pharm Sci       Date:  2021-02-25       Impact factor: 6.598

10.  A platelet-mimicking theranostic platform for cancer interstitial brachytherapy.

Authors:  Meng Lyu; Mingzhu Chen; Lujie Liu; Daoming Zhu; Xianjia Wu; Yang Li; Lang Rao; Zhirong Bao
Journal:  Theranostics       Date:  2021-06-04       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.